lixisenatide glp 1 The European Commission Approves Sanofi and Zealand Pharma's GLP-1 Agonist Lyxumia (lixisenatide) Lixisenatide | C215H347N61O65S | CID
Pay in 4 interest-free payments of $5.99 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5























